Comparable stake leader
VANGUARD GROUP INC
SEC ownership of Avidity Biosciences, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001599901.
Disclosed value leader
Avoro Capital Advisors LLC
Comparable rows
8/10
Latest evidence
30 Jun 2026
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
VANGUARD GROUP INC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
8 of 10
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
VANGUARD GROUP INC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001599901
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Avidity Biosciences, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD GROUP INC
Disclosed value leader
Avoro Capital Advisors LLC
Comparable rows
8/10
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 9.6%
2 rows are not safely comparable across share classes.
13D/G row: VANGUARD GROUP INC
Showing 1-8 of 10 holder rows.
Quick read
VANGUARD GROUP INC leads the comparable SEC ownership view at 9.6%.
8 of 10 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD GROUP INC's linked filing trail.
Comparable ownership
Top 5
VANGUARD GROUP INC
9.6%
BlackRock, Inc.
6.4%
Avoro Capital Advisors LLC
5.5%
Janus Henderson Group Ltd.
4.6%
RTW INVESTMENTS, LP
3.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 10 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13D/G
The Vanguard Group
|
9.6%
|
$575,984,900
13,219,759 shares
|
$0 | 30 Sep 2025 |
| BlackRock, Inc. |
13D/G
|
6.4%
|
$376,086,262
8,631,771 shares
|
-$17,916,333 | 30 Sep 2025 |
| Avoro Capital Advisors LLC |
13D/G
|
5.5%
|
$614,244,077
8,515,792 shares
|
$0 | 31 Dec 2025 |
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
4.6%
|
$500,546,351
6,939,503 shares
|
-$92,717,850 | 31 Dec 2025 |
| RTW INVESTMENTS, LP |
13D/G
3/4/5
10%+ Owner
|
3.1%
|
$204,173,813
4,686,110 shares
|
$0 | 27 Oct 2025 |
| FMR LLC |
13D/G
|
2.1%
|
$128,911,093
2,958,712 shares
|
-$809,934,537 | 31 Oct 2025 |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
|
0.5%
|
$52,158,501
723,118 shares
|
-$646,388,523 | 31 Dec 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13D/G
T. Rowe Price Associates, Inc.
|
0.1%
|
$10,306,511
142,888 shares
|
-$695,695,581 | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$5,721,892.
Buys
$0
Insiders: 0
Sells
$5,721,892
Insiders: 9
Net
-$5,721,892
Shares: -89,386
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 89,386
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 58,407 | $0 | $4,226,448 | -$4,226,448 |
| 9-12 | 0 | 30,979 | $0 | $1,495,444 | -$1,495,444 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to Avidity Biosciences, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
RTW INVESTMENTS, LP
Net 12M change
-$5,721,892
Latest report
27 Feb 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 10%+ Owner | $48,573,350 | Mixed | 04 Aug 2021 | ||
| Simona Skerjanec | Director | $0 | Mixed | 27 Feb 2026 | ||
| Teresa McCarthy | Chief Human Resources Officer | $0 | -$1,357,196 | -100% | Mixed | 27 Feb 2026 |
| Sarah Boyce | President and CEO, Director | $0 | -$1,661,783 | -100% | Mixed | 27 Feb 2026 |
| Michael F. MacLean | Chief Financial Officer | $0 | -$471,650 | -100% | Mixed | 27 Feb 2026 |
| Carsten Boess | Director | $0 | Mixed | 27 Feb 2026 | ||
| Steven George Hughes | Chief Medical Officer | $0 | -$720,660 | -100% | Mixed | 27 Feb 2026 |
| Kathleen P. Gallagher | Chief Program Officer | $0 | Mixed | 27 Feb 2026 | ||
| Tamar Thompson | Director | $0 | Mixed | 27 Feb 2026 | ||
| Jean Jinsun Kim | Director | $0 | Mixed | 27 Feb 2026 | ||
| Edward M. Kaye MD | Director | $0 | Mixed | 27 Feb 2026 | ||
| Noreen Henig | Director | $0 | Mixed | 27 Feb 2026 | ||
| Charles Calderaro III | Chief Technical Officer | $0 | -$269,201 | -100% | Mixed | 27 Feb 2026 |
| Troy E. Wilson | Director | $0 | Mixed | 27 Feb 2026 | ||
| Arthur A. Levin | Director | $0 | -$127,367 | -100% | Mixed | 27 Feb 2026 |
| W. Michael Flanagan | Chief Scientific Officer | $0 | -$644,790 | -100% | Mixed | 27 Feb 2026 |
| John B. Moriarty Jr. | Chief Legal Officer | $0 | -$171,474 | -100% | Mixed | 27 Feb 2026 |
| Eric Mosbrooker | Chief Commercial Officer | $0 | -$297,771 | -100% | Mixed | 27 Feb 2026 |
| Roderick Wong | Director, 10%+ Owner | Mixed | 16 Jun 2021 |
Recent insider transactions for Avidity Biosciences, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Teresa McCarthy | RNA | Common Stock | Disposed to Issuer | -100% | -165,296 | 0 | 27 Feb 2026 | Direct | ||
| Teresa McCarthy | RNA | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -518,500 | 0 | 27 Feb 2026 | Direct | ||
| Tamar Thompson | RNA | Common Stock | Disposed to Issuer | -100% | -6,692 | 0 | 27 Feb 2026 | Direct | ||
| Tamar Thompson | RNA | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -67,523 | 0 | 27 Feb 2026 | Direct | ||
| Michael F. MacLean | RNA | Common Stock | Disposed to Issuer | -100% | -133,977 | 0 | 27 Feb 2026 | Direct | ||
| Michael F. MacLean | RNA | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -587,375 | 0 | 27 Feb 2026 | Direct | ||
| Simona Skerjanec | RNA | Common Stock | Disposed to Issuer | -100% | -6,692 | 0 | 27 Feb 2026 | Direct | ||
| Simona Skerjanec | RNA | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -52,342 | 0 | 27 Feb 2026 | Direct | ||
| Steven George Hughes | RNA | Common Stock | Disposed to Issuer | -100% | -115,857 | 0 | 27 Feb 2026 | Direct | ||
| Steven George Hughes | RNA | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -315,133 | 0 | 27 Feb 2026 | Direct | ||
| Sarah Boyce | RNA | Common Stock | Disposed to Issuer | -100% | -474,861 | 0 | 27 Feb 2026 | Direct | ||
| Sarah Boyce | RNA | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -2,176,015 | 0 | 27 Feb 2026 | Direct | ||
| John B. Moriarty | RNA | Common Stock | Disposed to Issuer | -100% | -92,054 | 0 | 27 Feb 2026 | Direct | ||
| John B. Moriarty | RNA | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -210,000 | 0 | 27 Feb 2026 | Direct | ||
| W. Michael Flanagan | RNA | Common Stock | Disposed to Issuer | -100% | -150,365 | 0 | 27 Feb 2026 | Direct | ||
| W. Michael Flanagan | RNA | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -397,500 | 0 | 27 Feb 2026 | Direct | ||
| Troy Edward Wilson | RNA | Common Stock | Disposed to Issuer | -100% | -13,711 | 0 | 27 Feb 2026 | By family trust | ||
| Troy Edward Wilson | RNA | Common Stock | Disposed to Issuer | -100% | -65,091 | 0 | 27 Feb 2026 | Direct | ||
| Troy Edward Wilson | RNA | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -38,523 | 0 | 27 Feb 2026 | Direct | ||
| Kathleen P. Gallagher | RNA | Common Stock | Disposed to Issuer | -100% | -80,303 | 0 | 27 Feb 2026 | Direct | ||
| Kathleen P. Gallagher | RNA | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -208,330 | 0 | 27 Feb 2026 | Direct | ||
| Noreen Henig | RNA | Common Stock | Disposed to Issuer | -100% | -6,692 | 0 | 27 Feb 2026 | Direct | ||
| Noreen Henig | RNA | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -103,380 | 0 | 27 Feb 2026 | Direct | ||
| Jean Jinsun Kim | RNA | Common Stock | Disposed to Issuer | -100% | -6,692 | 0 | 27 Feb 2026 | Direct | ||
| Jean Jinsun Kim | RNA | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -97,523 | 0 | 27 Feb 2026 | Direct | ||
| Arthur A. Levin | RNA | Common Stock | Disposed to Issuer | -100% | -131,372 | 0 | 27 Feb 2026 | By family trust | ||
| Arthur A. Levin | RNA | Common Stock | Disposed to Issuer | -100% | -16,562 | 0 | 27 Feb 2026 | Direct | ||
| Arthur A. Levin | RNA | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -295,523 | 0 | 27 Feb 2026 | Direct | ||
| Edward M. Kaye MD | RNA | Common Stock | Disposed to Issuer | -100% | -6,692 | 0 | 27 Feb 2026 | Direct | ||
| Edward M. Kaye MD | RNA | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -103,380 | 0 | 27 Feb 2026 | Direct | ||
| Carsten Boess | RNA | Common Stock | Disposed to Issuer | -100% | -6,692 | 0 | 27 Feb 2026 | Direct | ||
| Carsten Boess | RNA | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -103,381 | 0 | 27 Feb 2026 | Direct | ||
| Eric Mosbrooker | RNA | Common Stock | Disposed to Issuer | -100% | -79,413 | 0 | 27 Feb 2026 | Direct | ||
| Eric Mosbrooker | RNA | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -227,188 | 0 | 27 Feb 2026 | Direct | ||
| Charles Calderaro III | RNA | Common Stock | Disposed to Issuer | -100% | -98,547 | 0 | 27 Feb 2026 | Direct | ||
| Charles Calderaro III | RNA | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -80,000 | 0 | 27 Feb 2026 | Direct | ||
| Steven George Hughes | RNA | Common Stock | Sale | -13.4% | $354,643 | $72.45 | -4,895 | 31,599 | 21 Jan 2026 | Direct |
| Sarah Boyce | RNA | Common Stock | Sale | -5.08% | $1,042,338 | $72.45 | -14,387 | 269,007 | 21 Jan 2026 | Direct |
| W. Michael Flanagan | RNA | Common Stock | Sale | -7.13% | $473,388 | $72.45 | -6,534 | 85,093 | 21 Jan 2026 | Direct |
| Teresa McCarthy | RNA | Common Stock | Sale | -2.51% | $212,206 | $72.45 | -2,929 | 113,938 | 21 Jan 2026 | Direct |
| Michael F. MacLean | RNA | Common Stock | Sale | -7.12% | $329,068 | $72.45 | -4,542 | 59,290 | 21 Jan 2026 | Direct |
| Arthur A. Levin | RNA | Common Stock | Sale | -9.6% | $127,367 | $72.45 | -1,758 | 16,562 | 21 Jan 2026 | Direct |
| Sarah Boyce | RNA | Common Stock | Sale | -2.94% | $619,444 | $72.23 | -8,576 | 283,394 | 07 Jan 2026 | Direct |
| Charles Calderaro III | RNA | Common Stock | Sale | -6.96% | $269,201 | $72.23 | -3,727 | 49,797 | 07 Jan 2026 | Direct |
| Teresa McCarthy | RNA | Common Stock | Sale | -1.65% | $141,932 | $72.23 | -1,965 | 116,867 | 07 Jan 2026 | Direct |
| John B. Moriarty | RNA | Common Stock | Sale | -3.09% | $171,474 | $72.23 | -2,374 | 74,557 | 07 Jan 2026 | Direct |
| Michael F. MacLean | RNA | Common Stock | Sale | -3% | $142,582 | $72.23 | -1,974 | 63,832 | 07 Jan 2026 | Direct |
| Steven George Hughes | RNA | Common Stock | Sale | -6.11% | $171,402 | $72.23 | -2,373 | 36,494 | 07 Jan 2026 | Direct |
| W. Michael Flanagan | RNA | Common Stock | Sale | -2.52% | $171,402 | $72.23 | -2,373 | 91,627 | 07 Jan 2026 | Direct |
| Arthur A. Levin | RNA | Common Stock | Gift | -6.77% | -1,330 | 18,320 | 19 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.